ID   FTC-236
AC   CVCL_2446
SY   FTC236
DR   BTO; BTO:0003875
DR   cancercelllines; CVCL_2446
DR   Cell_Model_Passport; SIDM00229
DR   Cosmic; 1239977
DR   ECACC; 06030202
DR   Wikidata; Q54835218
RX   PubMed=1384245;
RX   PubMed=29066502;
RX   PubMed=30737244;
RX   PubMed=31443247;
CC   Population: Caucasian.
CC   Characteristics: Has a near-homozygous genome (NHG) (PubMed=29066502).
CC   Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Lys1045fs (c.3135delG); Zygosity=Homozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Arg130Ter (c.388C>T); ClinVar=VCV000007819; Zygosity=Homozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 9884; RB1; Simple; p.Arg320Ter (c.958C>T); ClinVar=VCV000126824; Zygosity=Homozygous (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Homozygous; Note=In promoter (PubMed=30737244).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (PubMed=30737244).
CC   Omics: Mitochondrial genome sequenced.
CC   Omics: Transcriptome analysis by microarray.
CC   Misspelling: CFT-236; PubMed=1384245; Note=In the French and Spanish abstracts where the abbreviation 'FTC' was translated to 'CFT' and thus also the cell line names.
CC   Derived from site: Metastatic; Cervical lymph node; UBERON=UBERON_0002429.
ST   Source(s): ECACC=06030202; PubMed=30737244
ST   Amelogenin: X
ST   CSF1PO: 10,11
ST   D13S317: 11
ST   D16S539: 11,12
ST   D18S51: 11,12
ST   D21S11: 32.2
ST   D3S1358: 15,16
ST   D5S818: 11,12
ST   D7S820: 9,10
ST   D8S1179: 10
ST   FGA: 21
ST   TH01: 9.3
ST   TPOX: 9
ST   vWA: 15,18
DI   NCIt; C8054; Thyroid gland follicular carcinoma
DI   ORDO; Orphanet_146; Differentiated thyroid carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_1219 ! FTC-133
OI   CVCL_2447 ! FTC-238
SX   Male
AG   42Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 20
//
RX   PubMed=1384245; DOI=10.1007/BF02067383;
RA   Demeure M.J., Damsky C.H., Elfman F., Goretzki P.E., Wong M.G.,
RA   Clark O.H.;
RT   "Invasion by cultured human follicular thyroid cancer correlates with
RT   increased beta 1 integrins and production of proteases.";
RL   World J. Surg. 16:770-776(1992).
//
RX   PubMed=29066502; DOI=10.1530/ERC-17-0288;
RA   Corver W.E., Demmers J., Oosting J., Sahraeian S., Boot A., Ruano D.,
RA   van Wezel T., Morreau H.;
RT   "ROS-induced near-homozygous genomes in thyroid cancer.";
RL   Endocr. Relat. Cancer 25:83-97(2018).
//
RX   PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953;
RA   Landa I., Pozdeyev N., Korch C.T., Marlow L.A., Smallridge R.C.,
RA   Copland J.A. III, Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N.,
RA   Tan A.-C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R.,
RA   Fagin J.A., Schweppe R.E.;
RT   "Comprehensive genetic characterization of human thyroid cancer cell
RT   lines: a validated panel for preclinical studies.";
RL   Clin. Cancer Res. 25:3141-3151(2019).
//
RX   PubMed=31443247; DOI=10.3390/cancers11081185;
RA   Aydemirli M.D., Corver W.E., Beuk R., Roepman P.,
RA   Solleveld-Westerink N., van Wezel T., Kapiteijn E.H.W., Morreau H.;
RT   "Targeted treatment options of recurrent radioactive iodine refractory
RT   Hurthle cell cancer.";
RL   Cancers (Basel) 11:1185.1-1185.16(2019).
//